• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Oncology in Advance – March 1st, 2007

  • — 2 Mar, 2007
Lorie Hughes
Lorie Hughes
Rachel Ellsworth
Rachel Ellsworth
Rowan Chlebowski
Rowan Chlebowski
Victor Vogel
Victor Vogel

Local Excision Alone for Selected Patients with Ductal Carcinoma In Situ?

REFERENCE: Abstract: 29
LORIE HUGHES, The Hope Center, Cartersville GA
The intergroup study E-5194 has found that local excision without radiation in patients with ductal carcinoma in situ is sufficient therapy for a selected group of patients. But Lorie Hughes told Karen Regester that it is not satisfactory for patients with high-grade malignancies.

Metastatic Cancer Molecules Can Differ from Primary Tumors: Implications for Therapy

REFERENCE: Abstract: Poster 4004
RACHEL ELLSWORTH, Windber Research Institute, Pennsylvania
Inappropriate breast cancer therapy may be given if the pathology of distant disease is not tested, according to the findings of a study announced at the Breast Cancer Symposium. Molecules of lymph node metastases were markedly different from those in primary tumors, so to avoid inappropriate treatment decisions, distant disease pathology should be assessed. Rachel Ellsworth discussed her group’s findings with Peter Goodwin.

A Low-Fat Diet Reduces Breast Cancer Recurrence Risk, and Extends Life

REFERENCE: Abstract: 32
ROWAN CHLEBOWSKI, LABioMed, Los Angeles
Women who ate less fat had fewer recurrences of breast cancer, and lived longer, the San Antonio conference heard. Mature results from the Women’s Intervention Nutrition Study (WINS) were presented by Rowan Chlebowski showing a reduction of recurrences and also longer survival among women on a low-fat diet as compared with women eating their usual diet. He discussed the results with Peter Goodwin.

STAR Trial Latest: Raloxifene and Tamoxifen Not Quite Equal for Breast Cancer Prevention

REFERENCE: Abstract: 33
VICTOR VOGEL, University of Pittsburgh
The selective estrogen receptor modulators tamoxifen and raloxifene are both recommended for preventing breast cancer in women judged to be at high risk. But mature data following unblinding of the NSABP Study of Tamoxifen and Raloxifene (STAR) trial show that although these agents are equal in prophylactic power, they have some differences in terms of their effect on in situ disease. Victor Vogel gave the latest news to Peter Goodwin during the Breast Cancer Symposium.


To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

You may also like...

  • Jorge Cortes Chronic myeloid leukaemia: third generation TKI, ponatinib, succeeds against the T 315 I mutation 18 Dec, 2012
  • Prostate cancer screening: French study finds more harm than good from PSA testing Prostate cancer screening: French study finds more harm than good from PSA testing 19 Nov, 2013
  • Ultrahypofractionated Radiation Just As Effective for Prostate Cancer Ultrahypofractionated Radiation Just As Effective for Prostate Cancer 16 May, 2018
  • Matt Galsky MD from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer 13 Mar, 2015
  • Previous story Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART?
  • Next story Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • New Front Line Standard for Older Patients with Chronic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
  • Home
  • Oncology
  • ASCO
  • Audio Journal of Oncology in Advance – March 1st, 2007

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.